You searched for Gout - Page 54 of 96

Abstract Number: 1987 • 2013 ACR/ARHP Annual Meeting
LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS
Fernando Perez-Ruiz^1,2 and Ana M. Herrero-Beites^2,3, ¹Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain
LIVER OUTCOMES IN GOUT PATIENTS TREATED WITH FEBUXOSTAT AND ALTERED LIVER FUNCTION TESTSBackground/Purpose: patients with significantly altered liver function test (LFTs) at screening do not…
Abstract Number: 1988 • 2013 ACR/ARHP Annual Meeting
Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 2012 United States National Health and Wellness Survey
Jasvinder A. Singh¹, Kathy Annunziata² and Puja Khanna³, ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²Kantar Health, Princeton, NJ, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Hyperuricemia and gout are associated with major cardiovascular and metabolic comorbidities. Recently published data on comorbidities and gout epidemiology in the US have been…
Abstract Number: 1939 • 2013 ACR/ARHP Annual Meeting
Assessing The Increasing Costs To Manage Patients With Gout By State
Aaron Davis¹ and Jason Wreath², ¹2 calle guijarro, Goutchoices.com, San Clemente, CA, ²Symphony Health, Phoenix, AZ
Background/Purpose: Gout is a chronic progressive disease and worldwide prevalence is increasing. After over 40 years with limited and inexpensive treatments several new and more…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout
Seoyoung C. Kim¹, Sebastian Schneeweiss², Niteesh Choudhry³, Jun Liu⁴, Robert J. Glynn³ and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…
Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Liseth Siemons¹ and Eswar Krishnan², ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Medicine, Stanford University, Palo Alto, CA
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…
Abstract Number: 1722 • 2013 ACR/ARHP Annual Meeting
Does Starting Allopurinol Prolong Acute Treated Gout?
Erica Hill¹, Jay B. Higgs², Karen Sky³, Michelle Sit⁴ and Angelique N. Collamer⁵, ¹Rheumatology, San Antonio Military Medical Center, Fort Sam Houston, TX, ²Rheumatology, San Antonio Military Medical Center, JBSA - Fort Sam Houston, TX, ³Rheumatology, US Department of Veterans Affairs, Alaska VA Healthcare System, Anchorage, AK, ⁴Subspecialty Clinic - Rheumatology, David Grant Medical Center, Travis AFB, CA, ⁵Internal Medicine, Langley AFB Hospital, Langley AFB, VA
Background/Purpose: Gout is a common cause of morbidity in the US population. Traditionally, allopurinol is not initiated during an acute episode to avoid prolonging…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…
Abstract Number: 1195 • 2013 ACR/ARHP Annual Meeting
Sex Differences In Gout Evaluation and Management
Leslie R. Harrold¹, Carol Etzel², Allan Gibofsky³, Joel M. Kremer⁴, Michael H. Pillinger⁵, Kenneth G. Saag⁶, Naomi Schlesinger⁷, Robert Terkeltaub⁸, Vanessa Cox² and Jeffrey D. Greenberg⁹, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc, Southborough, MA, ³Medicine and Public Health, Hospital for Special Surgery, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁹Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Little is known regarding the evaluation, characteristics and management of women with gout. To characterize potential gender differences, we therefore compared clinical manifestations and…
Abstract Number: 1196 • 2013 ACR/ARHP Annual Meeting
Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout
Mireille Aujero¹, J. Steuart Richards², Carl A. Nunziato³, David D. Maron⁴ and Gail S. Kerr⁵, ¹Rheuamtology Section, Washington DC VA Medical Center and Georgetown University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Howard University Hospital, Washington, DC, ⁴Research Department, Washington DC VA Medical Center, Washington, DC, ⁵Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: ACR 2012 management guidelines for tophaceous gout (TG) recommend urate lowering therapies (ULT) to achieve a target serum uric acid (SUA) of < 6.0…
Abstract Number: 1197 • 2013 ACR/ARHP Annual Meeting
Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study
Weiqi Wang¹, Vidula Bhole² and Eswar Krishnan³, ¹medicine, stanford university, palo alto, CA, ²EpiSolutions Consultancy Services, Thane, India, ³Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Recent studies suggest a protective association between both urate lowering medications and colchicine and the risk for coronary heart disease. The goal of the…
Abstract Number: 1198 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years
Nicole Coman-Wright¹, Peter T. Chapman², John L. O'Donnell³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Gout is a common form of inflammatory arthritis caused by the crystallisation of uric acid. Sustained reduction of SU below 6mg/dl is critical for…
Abstract Number: 1199 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Novel Scoring System In The Differential Diagnosis Between Acute Gout and Septic Arthritis
Jung-Soo Song¹, Kwang-Hoon Lee², Sang Tae Choi¹, Eun-Jin Kang³ and You-Jung Ha⁴, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Dongguk University Ilsan Hospital, Goyang, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Recently, a novel scoring system was developed for the diagnosis of gout without joint fluid analysis (1). The performance of this scoring system in the…
Abstract Number: 1200 • 2013 ACR/ARHP Annual Meeting
Proportion Of Patients Achieving Serum Urate Target In a Longitudinal Veterans Administration (VA) Gout Registry: Crystal Registry
Puja Khanna^1,2, Andreas M. Reimold³, Gail S. Kerr⁴, J. Steuart Richards⁵, Elizabeth Chang⁶, Jasvinder A. Singh⁷, H. Ralph Schumacher⁸, Tanima Bannerjee⁹ and Dinesh Khanna¹⁰, ¹Rheumatology, Ann Arbor VA, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Washington DC VAMC and Georgetown University, Washington, DC, ⁶Phoenix VAHCS, Phoenix, AZ, ⁷Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁸Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁹Biostatistics, University of Michigan, Ann Arbor, MI, ¹⁰University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Gout is the most common inflammatory arthritis managed by healthcare providers at the VA Healthcare System. CRYSTAL registry is a longitudinal observational study at…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…

LIVER Outcomes In Gout Patients Treated With Febuxostat and Altered LIVER Function TESTS

Self-Reported Gout, Comorbidities and Healthcare Resource Utilization Data From The 2012 United States National Health and Wellness Survey

Assessing The Increasing Costs To Manage Patients With Gout By State

Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition

Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout

A Prediction Tool for Incident Gout Among Those With Hyperuricemia

Does Starting Allopurinol Prolong Acute Treated Gout?

Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers

Sex Differences In Gout Evaluation and Management

Chronic Renal Injury Does Not Prevent Achievement Of Target Serum Uric Acid In Tophaceous Gout

Gout Medications and The Risk For Incident Coronary Heart Disease and Stroke: The Framingham Heart Study

Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years

The Performance Of a Novel Scoring System In The Differential Diagnosis Between Acute Gout and Septic Arthritis

Proportion Of Patients Achieving Serum Urate Target In a Longitudinal Veterans Administration (VA) Gout Registry: Crystal Registry

ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load

Simple Search Results